Vildagliptin is a potent selective inhibitor of dipeptidyl peptidase‐4 (DPP‐4) that improves
glycaemic control by increasing islet α‐cell and β‐cell responsiveness to glucose. In patients …

ABSTRACT Preclinical Research The majority of studies on vildagliptin and pioglitazone
have focused on their combination in glycemic control. The aim of the present study was to …

Sitagliptin and vildagliptin represent a new class of anti-diabetic agents that enhance the
action of incretin hormones through inhibition of dipeptidyl peptidase-4 (DPP-4), the enzyme …

Dipeptidyl peptidase 4 (DPP-4) is a serine protease enzyme expressed widely in many
tissues, including the cardiovascular system. The incretin hormones such as glucagon-like …

Background We evaluated the effects of two dipeptidyl peptidase-4 (DPP-4) inhibitors,
sitagliptin and vildagliptin, on metabolic parameters in patients with type 2 diabetes mellitus …

Introduction We have previously shown modest weight loss with vildagliptin treatment. Since
body weight balance is associated with changes in blood pressure (BP) and fasting lipids …

Vildagliptin is a competitive and reversible inhibitor of dipeptidyl peptidase-4. Dipeptidyl
peptidase-4 inhibitors act mainly by preventing the rapid degradation of glucagon-like …

Introduction: Inhibition of dipeptidyl peptidase IV (DPP-4) augments glucose-dependent
insulin release and is a new approach to the treatment of type 2 diabetes (T2DM) …

Inhibition of dipeptidyl peptidase‐4 (DPP‐4) by vildagliptin prevents degradation of
glucagon‐like peptide‐1 (GLP‐1) and reduces glycaemia in patients with type 2 diabetes …

Background Progressive remodeling after myocardial infarction (MI) is a leading cause of
morbidity and mortality. Recently, glucagon-like peptide (GLP)-1 was shown to have …